274 related articles for article (PubMed ID: 22645712)
1. Molecular targets for radiation oncology in prostate cancer.
Wang T; Languino LR; Lian J; Stein G; Blute M; Fitzgerald TJ
Front Oncol; 2011; 1():17. PubMed ID: 22645712
[TBL] [Abstract][Full Text] [Related]
2. Molecular therapeutics in prostate cancer.
Nicholson B; Theodorescu D
Histol Histopathol; 2003 Jan; 18(1):275-98. PubMed ID: 12507306
[TBL] [Abstract][Full Text] [Related]
3. Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.
Vellky JE; Bauman TM; Ricke EA; Huang W; Ricke WA
Prostate; 2019 Dec; 79(16):1811-1822. PubMed ID: 31503366
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
5. Salicylate enhances the response of prostate cancer to radiotherapy.
Broadfield LA; Marcinko K; Tsakiridis E; Zacharidis PG; Villani L; Lally JSV; Menjolian G; Maharaj D; Mathurin T; Smoke M; Farrell T; Muti P; Steinberg GR; Tsakiridis T
Prostate; 2019 Apr; 79(5):489-497. PubMed ID: 30609074
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer.
Sehgal PD; Bauman TM; Nicholson TM; Vellky JE; Ricke EA; Tang W; Xu W; Huang W; Ricke WA
Hum Pathol; 2019 Jul; 89():99-108. PubMed ID: 31054895
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
9. Length and somatic mosaicism of CAG and GGN repeats in the androgen receptor gene and the risk of prostate cancer in men with benign prostatic hyperplasia.
Tayeb MT; Clark C; Murray GI; Sharp L; Haites NE; McLeod HL
Ann Saudi Med; 2004; 24(1):21-6. PubMed ID: 15310009
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
11. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Szostak MJ; Kyprianou N
Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways.
Rashid A; Liu C; Sanli T; Tsiani E; Singh G; Bristow RG; Dayes I; Lukka H; Wright J; Tsakiridis T
Radiat Oncol; 2011 Oct; 6():144. PubMed ID: 22029423
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
[TBL] [Abstract][Full Text] [Related]
14. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
15. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
Kageyama Y; Hyochi N; Kihara K; Sugiyama H
Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
[TBL] [Abstract][Full Text] [Related]
16. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
17. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
Mulholland DJ; Dedhar S; Wu H; Nelson CC
Oncogene; 2006 Jan; 25(3):329-37. PubMed ID: 16421604
[TBL] [Abstract][Full Text] [Related]
18. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
[TBL] [Abstract][Full Text] [Related]
19. The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT
Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
